180 related articles for article (PubMed ID: 36710133)
21. NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.
Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath KV; Wessells H
NIH Consens State Sci Statements; 2011 Dec 5-7; 28(1):1-27. PubMed ID: 23392076
[TBL] [Abstract][Full Text] [Related]
22. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
Chesnut GT; Vertosick EA; Benfante N; Sjoberg DD; Fainberg J; Lee T; Eastham J; Laudone V; Scardino P; Touijer K; Vickers A; Ehdaie B
Eur Urol; 2020 Apr; 77(4):501-507. PubMed ID: 31874726
[TBL] [Abstract][Full Text] [Related]
23. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
Lam TBL; MacLennan S; Willemse PM; Mason MD; Plass K; Shepherd R; Baanders R; Bangma CH; Bjartell A; Bossi A; Briers E; Briganti A; Buddingh KT; Catto JWF; Colecchia M; Cox BW; Cumberbatch MG; Davies J; Davis NF; De Santis M; Dell'Oglio P; Deschamps A; Donaldson JF; Egawa S; Fankhauser CD; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Gross T; Grummet JP; Henry AM; Ingels A; Irani J; Lardas M; Liew M; Lin DW; Moris L; Omar MI; Pang KH; Paterson CC; Renard-Penna R; Ribal MJ; Roobol MJ; Rouprêt M; Rouvière O; Sancho Pardo G; Richenberg J; Schoots IG; Sedelaar JPM; Stricker P; Tilki D; Vahr Lauridsen S; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; van Leenders GJLH; Varma M; Violette PD; Wallis CJD; Wiegel T; Wilkinson K; Zattoni F; N'Dow JMO; Van Poppel H; Cornford P; Mottet N
Eur Urol; 2019 Dec; 76(6):790-813. PubMed ID: 31587989
[TBL] [Abstract][Full Text] [Related]
24. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
26. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
27. The diagnostics of prostate cancer is changing.
Sandeman K; Rannikko A; Kenttämies A; Mirtti T
Duodecim; 2016; 132(24):2351-8. PubMed ID: 29199795
[TBL] [Abstract][Full Text] [Related]
28. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
29. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
30. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
Tomer A; Rizopoulos D; Nieboer D; Drost FJ; Roobol MJ; Steyerberg EW
Med Decis Making; 2019 Jul; 39(5):499-508. PubMed ID: 31319751
[No Abstract] [Full Text] [Related]
31. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
[TBL] [Abstract][Full Text] [Related]
32. Is Active Surveillance Too Active?
Kearns JT; Helfand BT
Curr Urol Rep; 2023 Oct; 24(10):463-469. PubMed ID: 37436691
[TBL] [Abstract][Full Text] [Related]
33. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.
Dieffenbacher S; Nyarangi-Dix J; Giganti F; Bonekamp D; Kesch C; Müller-Wolf MB; Schütz V; Gasch C; Hatiboglu G; Hauffe M; Stenzinger A; Duensing S; Schlemmer HP; Moore CM; Hohenfellner M; Radtke JP
Eur Urol Focus; 2021 Jan; 7(1):102-110. PubMed ID: 30878348
[TBL] [Abstract][Full Text] [Related]
34. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
35. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.
Muller BG; van den Bos W; Brausi M; Fütterer JJ; Ghai S; Pinto PA; Popeneciu IV; de Reijke TM; Robertson C; de la Rosette JJ; Scionti S; Turkbey B; Wijkstra H; Ukimura O; Polascik TJ
World J Urol; 2015 Oct; 33(10):1503-9. PubMed ID: 25559111
[TBL] [Abstract][Full Text] [Related]
36. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
[TBL] [Abstract][Full Text] [Related]
37. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P;
J Urol; 2013 Jan; 189(1 Suppl):S2-S11. PubMed ID: 23234625
[TBL] [Abstract][Full Text] [Related]
38. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
Moore CM; Kasivisvanathan V; Eggener S; Emberton M; Fütterer JJ; Gill IS; Grubb Iii RL; Hadaschik B; Klotz L; Margolis DJ; Marks LS; Melamed J; Oto A; Palmer SL; Pinto P; Puech P; Punwani S; Rosenkrantz AB; Schoots IG; Simon R; Taneja SS; Turkbey B; Ukimura O; van der Meulen J; Villers A; Watanabe Y;
Eur Urol; 2013 Oct; 64(4):544-52. PubMed ID: 23537686
[TBL] [Abstract][Full Text] [Related]
39. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
[TBL] [Abstract][Full Text] [Related]
40. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
